Loading
Loading
Research Overview
Synthetic FG-loop peptide modelled on the NCAM FG-loop domain; binds and activates FGFR1, triggering downstream ERK/MAPK and PI3K signalling cascades associated with synaptogenesis and memory consolidation.
FGL (FG-loop peptide) was engineered to mimic the FG-loop region of the neural cell adhesion molecule NCAM, which is known to interact with fibroblast growth factor receptors. By binding FGFR1, FGL activates downstream signalling cascades associated with synapse formation, synaptic plasticity, and memory consolidation in animal research models.
Preclinical research has examined FGL's effects on learning and memory tasks in rodent models, including tests of spatial memory, associative learning, and cognitive flexibility. The proposed mechanism — FGFR1-mediated neurotrophic signalling — is relevant to neuroplasticity and the biological processes underlying long-term potentiation.
FGL has a short half-life (hours) and is administered subcutaneously or intranasally in research protocols. No standardised human dose exists and no clinical trials have been conducted. It represents a research tool for NCAM-FGFR1 pathway biology rather than an established cognitive protocol compound.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, fgl (fg-loop peptide) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
FGL (FG-Loop Peptide) research is most relevant to protocols examining:
Synaptogenesis and memory consolidation research
NCAM/FGFR1 signalling pathway biology studies
ERK/MAPK downstream neuroplasticity investigations
Researchers studying cell adhesion molecule-derived peptides
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Synthetic FG-loop peptide modelled on the NCAM FG-loop domain; binds and activates FGFR1, triggering downstream ERK/MAPK and PI3K signalling cascades associated with synaptogenesis and memory consolidation.
| Parameter | Value |
|---|---|
| Dose range | No human protocol established |
| Schedule | Daily (animal models) |
| Route | Subcutaneous, Intranasal |
| Half-life | ~Hours |
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.